[1]
|
Seymour, C.W., Liu, V.X., Iwashyna, T.J., et al. (2016) Assessment of Clinical Criteria for Sepsis. JAMA, 315, 762-774. https://doi.org/10.1001/jama.2016.0288
|
[2]
|
Van Der Poll, T., Schultz, M. and Levi, M. (2013) Sepsis and Thrombosis. Seminars in Thrombosis and Hemostasis, 39, 559-566. https://doi.org/10.1055/s-0033-1343894
|
[3]
|
Colucci, M., Semeraro, F., Ammollo, C., et al. (2015) Coagulopathy of Acute Sepsis. Seminars in Thrombosis and Hemostasis, 41, 650-658. https://doi.org/10.1055/s-0035-1556730
|
[4]
|
Giustozzi, M., Ehrlinder, H., Bongiovanni, D., et al. (2021) Coagulopathy and Sepsis: Pathophysiology, Clinical Manifestations and Treatment. Blood Reviews, 50, Article ID: 100864. https://doi.org/10.1016/j.blre.2021.100864
|
[5]
|
Ince, C. (2005) The Microcirculation Is the Motor of Sepsis. Critical Care, 9, S13-S19. https://doi.org/10.1186/cc3753
|
[6]
|
Walborn, A., Rondina, M., Mosier, M., et al. (2019) Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 25. https://doi.org/10.1177/1076029619852163
|
[7]
|
Iba, T. and Levy, J.H. (2018) Inflammation and Thrombosis: Roles of Neutrophils, Platelets and Endothelial Cells and Their Interactions in Thrombus Formation during Sepsis. Journal of Thrombosis and Haemostasis, 16, 231-241. https://doi.org/10.1111/jth.13911
|
[8]
|
Evans, C.E., Spier, A.B. and Zhao, Y.Y. (2018) Sepsis-Induced Thrombus Formation and Cell-Specific HIFs. Thrombosis Research, 171, 187-189. https://doi.org/10.1016/j.thromres.2018.08.017
|
[9]
|
Iba, T., Levi, M. and Levy, J.H. (2020) Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 46, 89-95. https://doi.org/10.1055/s-0039-1694995
|
[10]
|
Seillier, C., Hélie, P., Petit, G., et al. (2022) Roles of the Tissue-Type Plasminogen Activator in Immune Response. Cellular Immunology, 371, Article ID: 104451. https://doi.org/10.1016/j.cellimm.2021.104451
|
[11]
|
Novokhatny, V.V., Ingham, K.C. and Medved, L.V. (1991) Domain Structure and Domain-Domain Interactions of Recombinant Tissue Plasminogen Activator. Journal of Biological Chemistry, 266, 12994-13002. https://doi.org/10.1016/S0021-9258(18)98794-6
|
[12]
|
Mehra, A., Ali, C., Parcq, J., et al. (2016) The Plasminogen Activation System in Neuroinflammation. Biochimica et Biophysica Acta, 1862, 395-402. https://doi.org/10.1016/j.bbadis.2015.10.011
|
[13]
|
Van Zonneveld, A.J., Veerman, H., Macdonald, M.E., et al. (1986) Structure and Function of Human Tissue-Type Plasminogen Activator (T-PA). Journal of Cellular Biochemistry, 32, 169-178. https://doi.org/10.1002/jcb.240320302
|
[14]
|
Lin, L. and Hu, K. (2014) Tissue Plasminogen Activator and Inflammation: From Phenotype to Signaling Mechanisms. American Journal of Clinical and Experimental Immunology, 3, 30-36.
|
[15]
|
Zhang, C., An, J., Strickland, D.K., et al. (2009) The Low-Density Lipoprotein Receptor-Related Protein 1 Mediates Tissue-Type Plasminogen Activator-Induced Microglial Activation in the Ischemic Brain. The American Journal of Pathology, 174, 586-594. https://doi.org/10.2353/ajpath.2009.080661
|
[16]
|
Uhl, B., Zuchtriegel, G., Puhr-Westerheide, D., et al. (2014) Tissue Plasminogen Activator Promotes Postischemic Neutrophil Recruitment via Its Proteolytic and Nonproteolytic Properties. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1495-1504. https://doi.org/10.1161/ATVBAHA.114.303721
|
[17]
|
Lin, L., Wu, C. and Hu, K. (2012) Tissue Plasminogen Activator Activates NF-κB through a Pathway Involving Annexin A2/CD11b and Integrin-Linked Kinase. Journal of the American Society of Nephrology, 23, 1329-1338. https://doi.org/10.1681/ASN.2011111123
|
[18]
|
Xiao, X., Zhang, H., Chen, H., et al. (2020) HSF1 Alleviates Microthrombosis and Multiple Organ Dysfunction in Mice with Sepsis by Upregulating the Transcription of Tissue-Type Plasminogen Activator. Thrombosis and Haemostasis, 121, 1066-1078. https://doi.org/10.1055/a-1333-7305
|
[19]
|
Renckens, R., Roelofs, J., Florquin, S., et al. (2006) Endogenous Tissue-Type Plasminogen Activator Is Protective during Escherichia Coli-Induced Abdominal Sepsis in Mice. The Journal of Immunology, 177, 1189-1196. https://doi.org/10.4049/jimmunol.177.2.1189
|
[20]
|
Renckens, R., Roelofs, J., Stegenga, M.E., et al. (2008) Transgenic Tissue‐Type Plasminogen Activator Expression Improves Host Defense during Klebsiella Pneumonia. Journal of Thrombosis and Haemostasis, 6, 660-668. https://doi.org/10.1111/j.1538-7836.2008.02892.x
|
[21]
|
Akol, H., Boon, E., Van Haren, F., et al. (2002) Successful Treatment of Fulminant Pneumococcal Sepsis with Recombinant Tissue Plasminogen Activator. European Journal of Internal Medicine, 13, 389-391. https://doi.org/10.1016/S0953-6205(02)00095-X
|
[22]
|
Aiuto, L.T., Barone, S.R., Cohen, P.S., et al. (1997) Recombinant Tissue Plasminogen Activator Restores Perfusion in Meningococcal Purpura Fulminans. Critical Care Medicine, 25, 1079-1082. https://doi.org/10.1097/00003246-199706000-00028
|
[23]
|
Zenz, W., Muntean, W., Gallistl, S., et al. (1995) Recombinant Tissue Plasminogen Activator Treatment in Two Infants with Fulminant Meningococcemia. Pediatrics, 96, 144-148. https://doi.org/10.1542/peds.96.1.144
|
[24]
|
Powers, W.J., Rabinstein, A.A., Ackerson, T., et al. (2019) Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 50, E344-E418. https://doi.org/10.1161/STR.0000000000000211
|
[25]
|
Colucci, M., Paramo, J.A. and Collen, D. (1986) Inhibition of One-Chain and Two-Chain Forms of Human Tissue-Type Plasminogen Activator by the Fast-Acting Inhibitor of Plasminogen Activator in Vitro and in Vivo. Journal of Laboratory and Clinical Medicine, 108, 53-59.
|
[26]
|
Hacke, W., Kaste, M., Bluhmki, E., et al. (2008) Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. The New England Journal of Medicine, 359, 1317-1329. https://doi.org/10.1056/NEJMoa0804656
|
[27]
|
Zhang, S., Zhou, Y., Li, R., et al. (2022) Advanced Drug Delivery System against Ischemic Stroke. Journal of Controlled Release, 344, 173-201. https://doi.org/10.1016/j.jconrel.2022.02.036
|
[28]
|
Correa-Paz, C., Navarro Poupard, M.F., Polo, E., et al. (2019) In Vivo Ultrasound-Activated Delivery of Recombinant Tissue Plasminogen Activator from the Cavity of Sub-Micrometric Capsules. Journal of Controlled Release, 308, 162-171. https://doi.org/10.1016/j.jconrel.2019.07.017
|
[29]
|
Ma, Y.H., Wu, S.Y., Wu, T., et al. (2009) Magnetically Targeted Thrombolysis with Recombinant Tissue Plasminogen Activator Bound to Polyacrylic Acid-Coated Nanoparticles. Biomaterials, 30, 3343-3351. https://doi.org/10.1016/j.biomaterials.2009.02.034
|
[30]
|
Chen, J.P., Liu, C.H., Hsu, H.L., et al. (2016) Magnetically Controlled Release of Recombinant Tissue Plasminogen Activator from Chitosan Nanocomposites for Targeted Thrombolysis. Journal of Materials Chemistry B, 4, 2578-2590. https://doi.org/10.1039/C5TB02579F
|
[31]
|
Tadayon, A., Jamshidi, R. and Esmaeili, A. (2016) Targeted Thrombolysis of Tissue Plasminogen Activator and Streptokinase with Extracellular Biosynthesis Nanoparticles Using Optimized Streptococcus Equi Supernatant. International Journal of Pharmaceutics, 501, 300-310. https://doi.org/10.1016/j.ijpharm.2016.02.011
|
[32]
|
Hu, J., Huang, S., Zhu, L., et al. (2018) Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke. ACS Applied Materials & Interfaces, 10, 32988-32997. https://doi.org/10.1021/acsami.8b09423
|
[33]
|
De Saint Victor, M., Barnsley, L.C., Carugo, D., et al. (2019) Sonothrombolysis with Magnetically Targeted Microbubbles. Ultrasound in Medicine and Biology, 45, 1151-1163. https://doi.org/10.1016/j.ultrasmedbio.2018.12.014
|
[34]
|
Liu, C.H., Hsu, H.L., Chen, J.P., et al. (2019) Thrombolysis Induced by Intravenous Administration of Plasminogen Activator in Magnetoliposomes: Dual Targeting by Magnetic and Thermal Manipulation. Nanomedicine, 20, Article ID: 101992. https://doi.org/10.1016/j.nano.2019.03.014
|
[35]
|
Zhang, B., Kim, H., Wu, H., et al. (2019) Sonothrombolysis with Magnetic Microbubbles under a Rotational Magnetic Field. Ultrasonics, 98, 62-71. https://doi.org/10.1016/j.ultras.2019.06.004
|
[36]
|
Yang, H.W., Hua, M.Y., Lin, K.J., et al. (2012) Bioconjugation of Recombinant Tissue Plasminogen Activator to Magnetic Nanocarriers for Targeted Thrombolysis. International Journal of Nanomedicine, 7, 5159-5173. https://doi.org/10.2147/IJN.S32939
|
[37]
|
Huang, L., Wang, J., Huang, S., et al. (2019) Polyacrylic Acid-Coated Nanoparticles Loaded with Recombinant Tissue Plasminogen Activator for the Treatment of Mice with Ischemic Stroke. Biochemical and Biophysical Research Communications, 516, 565-570. https://doi.org/10.1016/j.bbrc.2019.06.079
|
[38]
|
Ma, H., Jiang, Z., Xu, J., et al. (2021) Targeted Nano-Delivery Strategies for Facilitating Thrombolysis Treatment in Ischemic Stroke. Drug Delivery, 28, 357-371. https://doi.org/10.1080/10717544.2021.1879315
|